(Q50759965)

18 March 2018

title

Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice. (English)

1 reference

18 March 2018

main subject

Astragalus membranaceus

1 reference

Zhi-Gang Yang

1

1 reference

18 March 2018

Hong-Xiang Sun

series ordinal

2

1 reference

18 March 2018

Wei-Huan Fang

series ordinal

3

1 reference

18 March 2018

language of work or name

English

0 references

publication date

1 October 2005

1 reference

18 March 2018

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

18 March 2018

volume

23

1 reference

18 March 2018

issue

44

1 reference

18 March 2018

page(s)

5196-5203

1 reference

18 March 2018

Recent developments in adjuvants for vaccines against infectious diseases

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Adjuvants designed for veterinary and human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Adjuvants--a classification and review of their modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

The effect of various adjuvants on the humoral immune response of sheep and cattle to soluble and membrane midgut antigens of Boophilus microplus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

The immunomodulatory effect of saikosaponin derivatives and the root extract ofBupleurum kaoi in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Ginseng and aluminium hydroxide act synergistically as vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Ginseng extract in aluminium hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Adjuvant effect of ginseng extracts on the immune responses to immunisation against Staphylococcus aureus in dairy cattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Isomerization and formulation stability of the vaccine adjuvant QS-21

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

QS-21 structure/function studies: effect of acylation on adjuvant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Chemical analysis of Radix Astragali (Huangqi) in China: a comparison with its adulterants and seasonal variations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Protective effects of Astragalus saponin I on early stage of diabetic nephropathy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Cycloartane saponins from Astragalus peregrinus as modulators of lymphocyte proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Cycloartane triterpene glycosides from astragalus trigonus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Immunostimulatory effects of cycloartane-type triterpene glycosides from astragalus species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Suppressive effect of Astragalus membranaceus Bunge on chemical hepatocarcinogenesis in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

A review of the pharmacology and toxicology ofAstragalus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Haemolytic time course differences between steroid and triterpenoid saponins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Adjuvant effect of Panax notoginseng saponins on the immune responses to ovalbumin in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Immunological-adjuvant saponins from the roots of Panax notoginseng

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Evaluation of canine lymphocyte proliferation: comparison of three different colorimetric methods with the 3H-thymidine incorporation assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

QS-21: a water-soluble triterpene glycoside adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Molecular structures of saponins from Quillaja saponaria Molina.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Separation and structural analysis of saponins in a bark extract from Quillaja saponaria Molina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Saponin and sapogenol. XXXIV. Chemical constituents of astragali radix, the root of Astragalus membranaceus Bunge. (1). Cycloastragenol, the 9,19-cyclolanostane-type aglycone of astragalosides, and the artifact aglycone astragenol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Saponin and sapogenol. XXXV. Chemical constituents of astragali radix, the root of Astragalus membranaceus Bunge. (2). Astragalosides I,II and IV, acetylastragaloside I and isoastragalosides I and II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Saponin and sapogenol. XXXVI. Chemical constituents of astragali radix, the root of Astragalus membranaceus Bunge. (3). Astragalosides III,V, and VI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Constituents of Astragalus membranaceus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Saponin and sapogenol. XXXVII. Chemical constituents of astragali radix, the root of Astragalus membranaceus Bunge. (4). Astragalosides VII and VIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Hemolysis of human erythrocytes with saponin affects the membrane structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

Structural and immunological characterization of the vaccine adjuvant QS-21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.016

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.06.016

1 reference

18 March 2018

1 reference

18 March 2018